124 related articles for article (PubMed ID: 9072586)
1. Surgery for a post-chemotherapy residual mass in seminoma.
Herr HW; Sheinfeld J; Puc HS; Heelan R; Bajorin DF; Mencel P; Bosl GJ; Motzer RJ
J Urol; 1997 Mar; 157(3):860-2. PubMed ID: 9072586
[TBL] [Abstract][Full Text] [Related]
2. Management of testicular seminoma advanced disease. Report on 14 cases and review of the literature.
Porcaro AB; Antoniolli SZ; Maffei N; Beltrami P; Bassetto MA; Curti P
Arch Ital Urol Androl; 2002 Jun; 74(2):81-5. PubMed ID: 12161942
[TBL] [Abstract][Full Text] [Related]
3. Management of post-chemotherapy residual masses in advanced seminoma.
Flechon A; Bompas E; Biron P; Droz JP
J Urol; 2002 Nov; 168(5):1975-9. PubMed ID: 12394688
[TBL] [Abstract][Full Text] [Related]
4. The management of residual masses after chemotherapy in metastatic seminoma.
Ravi R; Ong J; Oliver RT; Badenoch DF; Fowler CG; Hendry WF
BJU Int; 1999 Apr; 83(6):649-53. PubMed ID: 10233573
[TBL] [Abstract][Full Text] [Related]
5. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center.
Puc HS; Heelan R; Mazumdar M; Herr H; Scheinfeld J; Vlamis V; Bajorin DF; Bosl GJ; Mencel P; Motzer RJ
J Clin Oncol; 1996 Feb; 14(2):454-60. PubMed ID: 8636757
[TBL] [Abstract][Full Text] [Related]
6. Postchemotherapy residual masses in advanced seminoma: current management and outcomes.
Quek ML; Simma-Chiang V; Stein JP; Pinski J; Quinn DI; Skinner DG
Expert Rev Anticancer Ther; 2005 Oct; 5(5):869-74. PubMed ID: 16221056
[TBL] [Abstract][Full Text] [Related]
7. The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma.
Hinz S; Schrader M; Kempkensteffen C; Bares R; Brenner W; Krege S; Franzius C; Kliesch S; Heicappel R; Miller K; de Wit M
J Urol; 2008 Mar; 179(3):936-40; discussion 940. PubMed ID: 18207171
[TBL] [Abstract][Full Text] [Related]
8. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals.
Becherer A; De Santis M; Karanikas G; Szabó M; Bokemeyer C; Dohmen BM; Pont J; Dudczak R; Dittrich C; Kletter K
Eur J Radiol; 2005 May; 54(2):284-8. PubMed ID: 15837411
[TBL] [Abstract][Full Text] [Related]
9. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial.
De Santis M; Becherer A; Bokemeyer C; Stoiber F; Oechsle K; Sellner F; Lang A; Kletter K; Dohmen BM; Dittrich C; Pont J
J Clin Oncol; 2004 Mar; 22(6):1034-9. PubMed ID: 15020605
[TBL] [Abstract][Full Text] [Related]
10. Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy.
Motzer R; Bosl G; Heelan R; Fair W; Whitmore W; Sogani P; Herr H; Morse M
J Clin Oncol; 1987 Jul; 5(7):1064-70. PubMed ID: 3598610
[TBL] [Abstract][Full Text] [Related]
11. Extensive surgery in metastatic testicular cancer.
Melchior D; Müller SC; Albers P
Aktuelle Urol; 2003 Jul; 34(4):214-22. PubMed ID: 14566667
[TBL] [Abstract][Full Text] [Related]
12. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma.
De Santis M; Bokemeyer C; Becherer A; Stoiber F; Oechsle K; Kletter K; Dohmen BM; Dittrich C; Pont J
J Clin Oncol; 2001 Sep; 19(17):3740-4. PubMed ID: 11533096
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy in advanced seminoma and the role of postcytostatic retroperitoneal lymph node dissection.
Hofmockel G; Gruss A; Theiss M
Urol Int; 1996; 57(1):38-42. PubMed ID: 8840489
[TBL] [Abstract][Full Text] [Related]
14. Gallium scans in the evaluation of residual masses after chemotherapy for seminoma.
Warren GP; Einhorn LH
J Clin Oncol; 1995 Nov; 13(11):2784-8. PubMed ID: 7595739
[TBL] [Abstract][Full Text] [Related]
15. Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma.
Ganjoo KN; Chan RJ; Sharma M; Einhorn LH
J Clin Oncol; 1999 Nov; 17(11):3457-60. PubMed ID: 10550142
[TBL] [Abstract][Full Text] [Related]
16. Clinical parameters that predict histology of postchemotherapy retroperitoneal lymph node mass in testicular cancer.
Onozawa M; Kawai K; Yamamoto T; Hinotsu S; Tsukamoto S; Hattori K; Miyanaga N; Shimazui T; Akaza H
Int J Urol; 2004 Jul; 11(7):535-41. PubMed ID: 15242364
[TBL] [Abstract][Full Text] [Related]
17. The significance of resections for residual masses after chemotherapy in metastatic testicular tumors.
Suzuki K; Orikasa S; Hoshi S; Yoshikawa K; Saito S; Ohyama C; Sato M; Kawamura S; Numahata K; Ito A; Tokuyama S
Int J Urol; 1999 Jun; 6(6):305-13. PubMed ID: 10404307
[TBL] [Abstract][Full Text] [Related]
18. [Management of residual masses of testis germ cell tumors].
Tremeau L; Mottet N
Bull Cancer; 2020 Feb; 107(2):215-223. PubMed ID: 31882267
[TBL] [Abstract][Full Text] [Related]
19. PET-CT for the management of testicular seminoma patients with post-chemotherapy residual masses.
Corsi O; Rada G; Peña J
Medwave; 2019 May; 19(4):e7625. PubMed ID: 31075095
[TBL] [Abstract][Full Text] [Related]
20. [Urologic treatment of testicular germ cell cancer].
Fernández Gómez JM; Escaf Barmadah S; Guate Ortiz JL; Martín Huescar A; Fresno Forcelledo F; García Rodríguez J; Rodríguez Faba O; Jalón Monzón A; Rodríguez Martínez JJ
Arch Esp Urol; 2002 Oct; 55(8):927-36. PubMed ID: 12455283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
